Thomas Kosasa

Director Thomas Kosasa buys 158.7K ONMD shares at $0.63; stock down 42.0% in 30 days, near 52-week lows

Thomas Kosasa purchased 158,730 shares at $0.63 on 2026-06-12, expanding his holdings to 17.09M shares (+0.9%). The transaction occurs in the context of severe recent price deterioration: the stock has fallen 42.0% over 30 days and trades at $0.54, representing a decline of 87.2% from its 52-week high of $4.22. At the same-ticker level, Kosasa's prior three completed ONMD buys all showed positive 90-day returns, with a timing pattern of 3 of 3 well-timed at the 90-day mark, though his most recent same-ticker purchase on 2026-05-18 and 2026-04-23 remain too recent for 90-day measurement. The underlying company presents fundamental headwinds: latest quarterly revenue was $96.0K, the firm generated a net loss of $2.5M, and despite annual revenue growth of 111.4%, the company remains unprofitable. This buy-on-weakness action by a substantial shareholder (now holding 17.09M shares) occurs as the stock approaches multi-year lows, but the timing signal is complicated by both the current downtrend and the immature revenue base relative to operating losses.

Director Kosasa Thomas buys 268,817 shares of ONMD at $0.93 for $249,999.81; stock now $0.87, -79.4% from 52-week high.

Kosasa Thomas, a director, purchased 268,817 shares at $0.93 on 2026-05-18, increasing holdings from 16,661,327 to 16,930,144 shares. The current price of $0.87 reflects a -7.0% decline over 30 days and positions the stock -79.4% below its 52-week high of $4.22. At the same-ticker level, Thomas's 5 prior purchases at ONMD show outcomes ranging from -19.0% to +151.8% in the first 30 days and -12.0% to +112.0% over 90 days, with 4 of 5 prior buys showing positive 90-day returns. The company's fundamentals are marked by significant unprofitability (net income of $-2,453,000.00 in the latest quarter, unprofitable full year) despite strong annual revenue growth of +111.4%. This buy occurs as the stock has recovered +28.6% over 90 days from recent lows but remains severely depressed relative to recent highs, warranting scrutiny of whether this accumulation reflects conviction or other factors in a micro-cap, loss-making business.

Director Kosasa Thomas purchased 876,136 shares across 2 tranches ($750.0K) at $0.84–$0.89; 5 of 5 prior ONMD buys achieved positive 90-day returns (38.2%–120.7%).

Director Kosasa Thomas completed 2 separate purchases totaling 876,136 shares for $749,999.14 at blended average price $0.86, increasing his holdings to 16.66M shares (+5.6%). His track record at ONMD is notably consistent: all 5 prior open-market buys at this ticker achieved positive 90-day returns ranging from 38.2% to 120.7%, with the most recent buy on 2025-09-24 returning +151.8% over 30 days. The current stock price of $1.10 is down 65.0% from the 52-week high of $3.14 but up 27.1% in the last 30 days and 12.2% over 90 days, placing this purchase in a period of recent momentum recovery. Against this backdrop of repeated well-timed accumulation at the same ticker, the filing signals continued conviction in the name after a steep drawdown from peak valuations.

Director Kosasa Thomas bought 1,879,871 shares for $1,049,474.52 across 5 transactions (avg $0.56); now holds 15,785,191 shares post-transaction.

Kosasa Thomas, a Director at OneMedNet Corp, executed five separate purchases totaling 1,879,871 shares (1.88M shares) for $1,049,474.52 between April and September 2025 at prices ranging from $0.38 to $0.93, with a blended average of $0.56. His holdings increased by 13.5% to 15,785,191 shares post-transaction. This accumulation occurs against a backdrop of significant financial deterioration: the company reported $177,000.00 in latest quarterly revenue with a net loss of $-741,000.00, annual revenue has declined 37.0%, and the stock has fallen 54.8% from its 52-week high and 37.7% over the past 30 days. The current stock price of $1.42 stands well above the blended transaction price of $0.56, suggesting the insider was purchasing at meaningfully depressed levels relative to recent valuations. The concentration of purchases and the accumulation pattern merit scrutiny given the company's unprofitability and deteriorating financial metrics.